Interferon alfa-2a (Roferon-A)

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Chronic myelogenous leukemia
• Follicular lymphoma
• Hairy cell leukemia
• Kaposi sarcoma
• Melanoma
• Neuroendocrine tumor
• Renal cell carcinoma
• Cutaneous squamous cell carcinoma

Diseases for which it was used

• Multiple myeloma

Patient drug information

• Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)

History of changes in FDA indication

• 6/4/1986: Initial FDA approval

Also known as

• Brand name: Roferon-A